


FTISADTSK acetate

Cat. No.: HY-P3146A
Molecular Formula: C₄₄H₇₂N₁₀O₁₈
Molecular Weight: 1029.1
Sequence Shortening: FTISADTSK
Target: Drug Metabolite
Pathway: Metabolic Enzyme/Protease
Storage: Sealed storage, away from moisture



Powder -80°C 2 years
 -20°C 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

SOLVENT & SOLUBILITY

In Vitro

H₂O : 50 mg/mL (48.59 mM; Need ultrasonic)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		0.9717 mL	4.8586 mL	9.7172 mL
	5 mM		0.1943 mL	0.9717 mL	1.9434 mL
	10 mM		0.0972 mL	0.4859 mL	0.9717 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

FTISADTSK acetate is an endogenous stable signature peptide from Trastuzumab monitored by selected reaction monitoring (SRM)^[1].

REFERENCES

[1]. Bults P, et al. LC-MS/MS-Based Monitoring of In Vivo Protein Biotransformation: Quantitative Determination of Trastuzumab and Its Deamidation Products in Human Plasma. Anal Chem. 2016;88(3):1871-1877.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA